Tuesday, June 1, 2021

AMGN: Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

New alert via PocketInfo for AMGN:

Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

Press Releases: http://www.amgen.com/media/pr.jsp
SEC Filings: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-sec
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8

No comments:

Post a Comment